Introduction
Patients with hematological malignancies can be successfully treated with allogeneic stem cell transplantation (allo-SCT). After allo-SCT relapse of the hematological malignancy can occur that can be successfully treated with donor lymphocyte infusion (DLI) from the original stem cell donor which can result in complete remissions 4, 5 . This graft versus leukemia (GvL) effect of DLI, however, is often accompanied by graft versus host disease (GvHD) causing serious mortality and morbidity. It has been demonstrated that donor T-cells recognizing minor histocompatibility antigens selectively expressed on hematopoietic cells mediate anti-leukemic reactivity after allo-SCT without causing GvHD 6, 7 . The minor histocompatibility antigen HA-1 is exclusively expressed on hematopoietic cells 1 , making it an attractive target antigen to treat hematological malignancies relapsing after allo-SCT when the patient is HA-1 + and the donor is HA-1 -. In addition, HA-1 is presented in the context of HLA-A*0201 8 and has a favorable population frequency 9 . In contrast to unmodified DLI, early administration of cytomegalovirus (CMV) or
Epstein-Barr virus (EBV)-specific donor T-cells does not lead to the development of GvHD.

Genetic engineering of donor T-cells recognizing viral antigens with HA-1-specific TCRs is
therefore an attractive strategy to induce anti-leukemic responses without the induction of GvHD.
Previously, we have shown the feasibility of this strategy by the efficient generation of redirected virus specific T-cells transduced with minor histocompatibility specific HA-2-TCRs. [10] [11] [12] .
However, transfer of the HA-1-TCR, although of interest for clinical application, did not result in efficient expression at the cell surface of HA-1-TCR engineered T cells 3 . In this study we describe different strategies to improve HA-1-TCR cell-surface expression after TCR gene transfer.
Design and Methods
Construction of HA-1-TCR encoding retroviral vectors
TCRAV and TCRBV gene usage of the HA-1-specific T-cell clone HA1.M7, determined as previously described 13 , was demonstrated to be AV32 and BV6S4. Wildtype (WT) and modified
TCRα and TCRβ chains were cloned separately into the retroviral vector LZRS, either in combination with eGFP (TCRα) or with NGF-R (TCRß) markergene. The single constructs in which the WT and modified HA-1-TCR chains were linked with a picornavirus-derived selfcleaving T2A sequence 14 were either expressed in the LZRS combined with the NGF-R markergene or in the MP71 vector without markergene. The HA-1-TCRβ chain comprising of the CDR1-region of the HA-2.20-TCR was obtained by two-step PCR. Primers used are depicted in Supplementary Table 1 . Codon-optimized TCR genes were designed and produced by GENEART(Regensburg, Germany). In addition, cysteine modified HA-1-TCR chains were constructed as previously described [15] [16] [17] . φ -NX-A cells were used to generate viral supernatant as previously described 10, 18 .
HLA class I tetramers and flow cytometric analyses
PE-or APC-conjugated tetramers were constructed as described with minor modifications 19 .
Tetramers used were composed of HLA-A2 and HA-1 peptide VLHDDLLEA (HA-1 VLH),
HLA-A1 and CMV-pp50 peptide VTEHDTLLY (pp50 VTE), HLA-B7 and CMV-pp65 TPRVTGGAM (pp65 TPR) or CMV-pp65 RPHERNGFTVL (pp65 RPH) and HLA-B8 and 
Isolation of virus-specific T-cells and retroviral transduction
All studies were conducted with approval of the institutional review board at Leiden University Medical Center. Virus-specific T-cells were isolated from PBMCs of CMV and EBV seropositive individuals. After informed consent, PBMCs were harvested, labeled with the relevant tetramers for 1 h at 4ºC, and sorted at 4ºC using the FACS Vantage (BD) into weak competitor phenotype pp50 VTE or pp65 RPH specific T-cells and strong competitor phenotype EBNA3A FLR or pp65 TPR specific T-cells with >95% purity. Virus-specific T-cells were stimulated as described previously 20 and transduced 2 days after stimulation with retroviral supernatant using CH-296 as described previously 20 . Markergene eGFP and NGF-R double positive T-cells were subsequently sorted. TCRαβ -/-Jurkat clone 76 18 (J76) needed no stimulation prior to transduction.
qRT-PCR
A qRT-PCR was performed to measure the mRNA level of TCRα chain and TCRß chain. Total 
Cytokine secretion assay and cytotoxicity assay
To test HA-1-specific functionality, 5.000 purified TCR transduced or mock transduced T-cells were cocultured with 20.000 different target cells and after overnight incubation specific IFN-γ production was measured by standard ELISA 21 . In addition, 50.000 virus-specific T-cells were tested one week after transduction with the clinical vector against 20.000 target cells. In the cytotoxicity assay purified TCR transduced or mock transduced T-cells were cocultured with different target cells at an 10:1 effector-to-target ratio and cytotoxic reactivity was determined after 4h 10 . The tests were done in triplicate. Targets used were HLA-A2 + HA-1 + or HA-1 -EBVtransformed lymphoblastoid cell lines (LCLs), and acute myeloid or lymphoblastoid leukemia (AML and ALL, respectively) primary cells.
Results and discussion
To investigate whether the sub-optimal cell-surface expression of the HA-1-TCR after gene transfer was due to intrinsic properties of the TCR, the HA-1-TCR cell-surface expression of five different parental HA-1-specific T-cell clones derived from different individuals was determined.
As demonstrated in Figure 1A , the HA-1-specific T-cell clones expressed significant lower levels of TCR-CD3 complexes at the cell-surface compared to HA-2- 18 or CMV A2 -specific 20 To be able to improve HA-1-TCR expression after gene transfer, we investigated whether we could determine the specific region of the HA-1-TCR BV6S4 ß chain responsible for this low TCR cell-surface expression. For this purpose, the sequences of 4 different TCRß chains belonging to the BV6 variable domain family and known to exhibit high cell-surface expression after gene transfer were aligned with the sequences of the HA-1-TCR BV6S4 ( Figure S1 ). Based on these sequence alignments, we hypothesized that primarily the CDR1-region of HA-1-TCR BV6S4 may influence cell-surface expression of the HA-1-TCRβ chain. However, exchange of the HA-1-TCR BV6S4 CDR1-region with the HA-2-TCR BV6S2 CDR1-region did not improve HA-1-TCR cell-surface expression ( Figure 1D , right panel), and resulted in abolished HA-1-specific reactivity ( Figure 1E ), indicating that the CDR1-region is modestly involved in low HA-1-TCR cell-surface expression, but crucial for HA-1-specificity.
Since apparently HA-1-TCR expression could not be improved by modification of specific sequences of the HA-1-TCRß chain, other strategies described to improve TCR cell-surface expression of gene transferred TCRs were explored. We studied whether TCR codon optimization 24 or cysteine modification 16, 17 Figure 3C ).
To study whether this improved HA-1-TCR cell-surface expression was coincided with clinically relevant HA-1-specific functionality, weak and strong competitor phenotype T-cells were transduced with single constructs encoding either unmodified HA-1-TCRα and ß chains or modified HA-1-TCRα and ß chains in combination with NGF-R, and analyzed for HA-1-specific cytotoxic activity ( Figure 2D and 3D, respectively) and IFN-γ production ( Figure 2E and 3E, respectively). Whereas weak competitor T-cells transduced with the unmodified HA-1-TCR exerted HA-1 specific cytotoxic reactivity and IFN-γ production against AML and ALL ( Figure   2D and 2E, respectively,), introduction of the modified TCR enhanced HA-1-specific reactivity ( Figure 2D and 2E ). In addition, strong competitor T-cells transduced with the modified HA-1-
TCR were able to demonstrate significant cytotoxic activity and IFN-γ production directed against HA-1 + malignant cells ( Figure 3D and 3E, respectively).These results demonstrate that introduction of the modified HA-1-TCR into both weak as well as strong competitor phenotype T-cells generated potent redirected HA-1-specific T-cells. 
